

## Accepted Abstracts

Abstract No.	First Name	Last Name	Program No.	Session	Session Title	Date	Time		Order	Session Room	Abstract Title
10150	Binyang	Xi	FRS6-2	Featured Research Session 6	Basic Research	3/22 (Sun)	10:30	12:00	2	Room 10	Analysis of Localization and Function of Ca <sup>2+</sup> Handling Proteins in Cardiac Fibroblasts
10644	Jie	Wang	FRS6-5	Featured Research Session 6	Basic Research	3/22 (Sun)	10:30	12:00	5	Room 10	Integrative Multiomics Analyses Identify GDF-15 for Vascular Aging
10737	Tetsuji	Shinohara	FRS1-5	Featured Research Session 1	Prognosis and Therapy	3/20 (Fri)	9:40	11:10	5	Room 10	Predictive Value of Notched P Waves for Life-Threatening Arrhythmias in Patients with Brugada Syndrome: a Multicenter Study in Japan
10744	Xiaoyue	Song	FRS6-4	Featured Research Session 6	Basic Research	3/22 (Sun)	10:30	12:00	4	Room 10	Endothelial GSDMD Induces Mitochondrial Damage and Activates the STING Pathway in Lipopolysaccharide-accelerated Atherosclerosis
11235	Shin	Nagai	FRS4-2	Featured Research Session 4	PCI and Risk Management 2	3/21 (Sat)	13:25	14:55	2	Room 10	Door-to-Unload Time and Mortality in Patients with ST-Segment Elevation Myocardial Infarction complicated by Cardiogenic Shock
12035	Aiko	Takami	FRS1-2	Featured Research Session 1	Prognosis and Therapy	3/20 (Fri)	9:40	11:10	2	Room 10	Long-Term Risk Stratification of Atrioventricular Block after AAI Pacing in Patients with Sick Sinus Syndrome
12080	Kenji	Ogata	FRS5-4	Featured Research Session 5	Lipid Management and Peripheral Artery Disease	3/22 (Sun)	8:00	9:30	4	Room 10	The Clinical Outcome of Drug-Coated Balloon following Jetstream and Drug-Coated Balloon for Femoropopliteal Nodular Calcification Lesions
12326	Qianqian	Guo	FRS6-3	Featured Research Session 6	Basic Research	3/22 (Sun)	10:30	12:00	3	Room 10	AM-RAMP3 Signaling Protects against Doxorubicin-Induced Cardiotoxicity by Suppressing Ferroptosis
70028	Yosuke	Nabeshima	FRS2-3	Featured Research Session 2	Heart Failure	3/20 (Fri)	13:40	15:10	3	Room 10	Who Will Respond to Sacubitril/Valsartan with NT-proBNP Reduction in Acute Heart Failure? Insights from the PREMIER Substudy
70031	Kouji	Kajinami	FRS5-3	Featured Research Session 5	Lipid Management and Peripheral Artery Disease	3/22 (Sun)	8:00	9:30	3	Room 10	Trends of Statin Prescription and Rhabdomyolysis Incident Report: a Nationwide Survey Using the NDB and JADER
70035	Keitaro	Senoo	FRS1-3	Featured Research Session 1	Prognosis and Therapy	3/20 (Fri)	9:40	11:10	3	Room 10	The safety and outcomes of catheter ablation for atrial fibrillation patients with heart failure
70036	Nobuaki	Hamazaki	FRS2-5	Featured Research Session 2	Heart Failure	3/20 (Fri)	13:40	15:10	5	Room 10	Beneficial Physiotherapy Approach to Prevent Hospitalization-Associated Disability in Older Patients with Heart Failure: a Post-Hoc Analysis from the J-Proof HF
70040	Maiku	Saji	FRS3-5	Featured Research Session 3	PCI and Risk Management 1	3/21 (Sat)	10:30	12:00	5	Room 10	Osteoporotic Risk and In-Hospital Mortality after Acute Myocardial Infarction: Insights from the Tokyo CCU Network Registry
70041	Masataka	Yoshinaga	FRS4-4	Featured Research Session 4	PCI and Risk Management 2	3/21 (Sat)	13:25	14:55	4	Room 10	Pilot clinical evaluation of Artificial Intelligence (AI)-driven guiding catheter simulation for optimizing percutaneous coronary intervention
70044	Kengo	Tanabe	FRS3-4	Featured Research Session 3	PCI and Risk Management 1	3/21 (Sat)	10:30	12:00	4	Room 10	Impact of High Bleeding Risk in PCI with Paclitaxel Drug Coated Balloon for De novo Lesions: Insights from ALLIANCE Registry
70063	Masami	Nishino	FRS2-4	Featured Research Session 2	Heart Failure	3/20 (Fri)	13:40	15:10	4	Room 10	Is $\beta$ -blocker Necessary for All Patients with Heart Failure with Preserved Ejection Fraction?: PurSuit-HFpEF Registry
70073	Hiroyuki	Takahama	FRS2-2	Featured Research Session 2	Heart Failure	3/20 (Fri)	13:40	15:10	2	Room 10	Prevalence and Prognosis of Stage B Heart Failure in the General Population: a 5-Year Follow-Up from the Tohoku Medical Megabank
70074	Hirofumi	Ohashi	FRS3-3	Featured Research Session 3	PCI and Risk Management 1	3/21 (Sat)	10:30	12:00	3	Room 10	Prognostic Impact of Renal Function on Outcomes after Physiology-Guided Coronary Revascularization
70085	Tamon	Katoh	FRS5-5	Featured Research Session 5	Lipid Management and Peripheral Artery Disease	3/22 (Sun)	8:00	9:30	5	Room 10	Temporal Trends in Patient Demographics and Outcomes of Patients Undergoing Endovascular Treatment: Insights from the I-PAD and SHINANO2 EVT Registries
70086	Yu	Kataoka	FRS5-2	Featured Research Session 5	Lipid Management and Peripheral Artery Disease	3/22 (Sun)	8:00	9:30	2	Room 10	Ongoing Cardiovascular Risks of Elevated Lipoprotein(a) Levels despite Achieving LDL-C < 55mg/dL: Cardiovascular Events & Analyses in Patients with Coronary Artery Disease
70096	Keijiro	Nakamura	FRS1-4	Featured Research Session 1	Prognosis and Therapy	3/20 (Fri)	9:40	11:10	4	Room 10	Machine Learning Based Risk Stratification after WATCHMAN Implantation in the TERMINATOR Registry
70100	Naotaka	Okamoto	FRS4-3	Featured Research Session 4	PCI and Risk Management 2	3/21 (Sat)	13:25	14:55	3	Room 10	Impact of Door-to-Unloading and Symptom-to-Unloading Times on 30-day Mortality in ST-elevation Myocardial Infarction Patients with Cardiogenic Shock: J-PVAD Registry
70130	Elfiany	Syafuruddin	FRS4-5	Featured Research Session 4	PCI and Risk Management 2	3/21 (Sat)	13:25	14:55	5	Room 10	Machine Learning Integration of Social Determinants and Clinical Risk Indicators Predicts Cardiovascular Mortality across Southeast Asia: a Country-Year Cohort Analysis
70135	Kazumasa	Ikeda	FRS3-2	Featured Research Session 3	PCI and Risk Management 1	3/21 (Sat)	10:30	12:00	2	Room 10	Prognostic Impact of a Pullback Pressure Gradient-Based Model on Clinical Outcomes after Percutaneous Coronary Intervention